Assessing Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After New SUBLOCADE Cost Savings Evidence In Corrections Settings

Indivior Pharmaceuticals (INDV) is back in focus after a new peer reviewed cost impact model suggested its monthly SUBLOCADE injection could reduce staff time and operational costs for treating opioid use disorder in correctional facilities.

See our latest analysis for Indivior Pharmaceuticals.

The new cost impact data lands after a volatile stretch for the stock, with the share price at US$30.47 and a 1 year total shareholder return of 224.84% alongside a 74.61% 3 year total shareholder return, suggesting strong momentum despite a weaker 90 day share price return of 14.72%.

If this kind of healthcare thesis interests you, it might be worth scanning for other treatment focused names through our screener of 37 healthcare AI stocks

With revenue of US$1.24b, net income of US$210m and a value score of 5, plus a share price sitting well below the average analyst target, should you view Indivior as mispriced value or as a company where the market is already pricing in future growth?

Most Popular Narrative: 19.5% Undervalued

Indivior’s most followed narrative tags a fair value of $37.86 against the latest close at $30.47, setting up a clear valuation gap for investors to interrogate.

The multiyear Indivior Action Agenda, including at least $150 million in annual operating expense savings and a capped 2026 operating budget of $450 million, is intended to materially lower the cost base and support the translation of revenue growth into earnings and cash flow expansion.

Read the complete narrative.

Want to see the math behind that valuation gap? The narrative leans on a mix of steady top line growth, sharply higher margins and a slimmer cost base. Interested in how those ingredients combine into that projected earnings profile and implied future P/E multiple? The full narrative sets out the playbook that underpins this fair value call.

Result: Fair Value of $37.86 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, there is still a chance that faster SUBLOCADE uptake or deeper cost savings could push earnings and cash flow well beyond what this fair value narrative assumes.

Find out about the key risks to this Indivior Pharmaceuticals narrative.

Next Steps

Given the mix of opportunity and concern in this story, it makes sense to review the underlying data for yourself and develop your own clear view using our breakdown of 4 key rewards and 3 important warning signs.

Looking for more investment ideas?

Do not stop with a single stock story when you can quickly scan curated ideas that match different goals, risk levels and income preferences in one place.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com